Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darbepoetin alfa versus placebo in anemic patients with advanced non-small cell lung cancer receiving chemotherapy
NL-OMON40053Phase 3Recruiting
- Sponsor
- Amgen
- Start
- Jan 2011
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in anaemia and non-small cell lung cancer (NSCLC) comparing Darbepoetin alfa plus chemotherapy with Placebo plus chemotherapy (2 arms). Primary endpoint: Overall survival non-inferiority. Started Jan 2011; status: recruiting.
02
Drugs
darbepoetin alfa
03
Conditions
anaemianon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON40053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40053.